Developer docs
API playgroundTry for free, no card

Search company profiles

Altis Biosystems

Full company profile

uuid0000n2a

Namestring
Altis Biosystems
Legal namestring
Altis Biosystems, Inc.
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Altis Biosystems is a privately held biotechnology company founded in 2015 and headquartered in Durham, North Carolina, that develops human intestinal epithelium models derived from adult donor stem cells for preclinical drug discovery and toxicology applications. Its core platform, RepliGut Systems, comprises RepliGut Planar (a reproducible, scalable human intestinal monolayer for drug disposition, pharmacology, ADME/DMPK, toxicity, and efficacy studies), RepliGut Crypt (capturing intestinal crypt architecture), and RepliGut Immune Co-Culture (a gut-immune model for inflammatory bowel disease research), complemented by catalog kit products and a human intestinal mucus offering.

The company monetizes through a hybrid B2B model: direct sales of ready-to-use kits and media products to pharma and biotech researchers, and fee-for-service contract research engagements including InflammaScreen (inflammation screening), StemTox (toxicity assessment), In Vitro DMPK, and custom research services. Pricing is not publicly disclosed; customers engage via website contact forms and direct sales outreach with multi-year contract terms typical of the life sciences tools segment. RepliGut products are positioned as New Approach Methodologies (NAMs) providing human-relevant, ethically sourced alternatives to animal testing for gastrointestinal toxicity prediction, drug absorption, metabolism, barrier function, and inflammatory response.

Altis serves pharmaceutical companies, biotechnology companies, and academic and contract research organizations, with named collaborations including Janssen R&D, Genentech, Fog Pharma, and CN Bio Innovations. The company maintains a scientific-publication-led go-to-market motion, leveraging peer-reviewed journals, conference presentations, and direct enterprise engagement, with Japan distribution handled via a partnership with Funakoshi, Ltd. As of April 2025, the company had raised approximately $6.6 million in disclosed equity funding across multiple rounds from investors including Hatteras Venture Partners, VentureSouth, and New Orleans BioFund, and operates with 11-50 employees organized around R&D, commercial strategy, operations, and quality assurance functions.

Short descriptiontext

Altis Biosystems is a Durham, NC-based biotechnology company developing RepliGut Systems, stem-cell-derived human intestinal epithelium models used by pharmaceutical and biotechnology companies for preclinical drug discovery, toxicology screening, and ADME/DMPK studies as alternatives to animal testing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
organ-on-chip models, preclinical drug discovery, human intestinal models, stem cell assays, GI toxicity screening
Industry2 codes
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code4 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
Product category
Preclinical Drug Discovery Tools
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1RepliGut Kit Sales
TypeOne Time License
Description

Sale of ready-to-use RepliGut Planar kits, RepliGut Crypt kits, and associated media products for compound screening, disease modeling, and microbiome research.

altisbiosystems.com
2Contract Research Services
TypeProfessional Services
Description

Fee-for-service offerings including InflammaScreen (inflammation screening), StemTox (toxicity assessment), and In Vitro DMPK studies conducted on behalf of pharmaceutical and biotech clients.

altisbiosystems.com
3Custom Service Engagements
TypeProfessional Services
Description

Bespoke research collaborations tailored to specific client drug development needs, leveraging the company's human intestinal model platform.

altisbiosystems.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Contact-based pricing for all products and services
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is not publicly disclosed. Customers initiate contact via website form or direct email to request quotes for RepliGut kits, media, and research services.

altisbiosystems.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Altis Biosystems develops and sells RepliGut Systems, a collection of in vitro human intestinal models derived from adult donor stem cells that replicate the structure of human small intestine and colonic epithelium. The portfolio includes RepliGut Planar, RepliGut Crypt, and RepliGut Immune Co-Culture platforms, complemented by ready-to-use RepliGut Kits, Intestinal Mucus products, and contract research services (InflammaScreen, StemTox, In Vitro DMPK, and Custom Services) for preclinical drug discovery, toxicology, ADME, and disease modeling applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • High-throughput assay for predicting diarrhea risk achieved 91% accuracy for proliferation, 90% for abundance, and 88% for barrier formation using RepliGut Planar model
+2 more records
Product overview1 text field

Altis Biosystems offers RepliGut® Systems, a collection of in vitro human intestinal models derived from stem cells, designed for pre-clinical drug discovery. The portfolio consists of three platform products (RepliGut® Planar, RepliGut® Crypt, and RepliGut® Immune Co-Culture) that replicate the complex structure of human small intestine and colonic epithelium. These are complemented by kit products (RepliGut® Kits and Intestinal Mucus) for laboratory use, and service offerings (InflammaScreen, StemTox, In Vitro DMPK, and Custom Services) that enable pharmaceutical companies to screen compounds for GI toxicity, evaluate inflammatory responses, and assess drug metabolism and bioavailability—all as alternatives to animal testing through New Approach Methodologies (NAMs).

Product and service9 records
1RepliGut® Planar
CategoryIn vitro human intestinal model platform
Description

A reproducible and scalable human intestine platform derived from adult donor stem cells, suitable for studying drug disposition, pharmacology, toxicity, metabolism, drug absorption, and efficacy in preclinical drug discovery. Designed for high-throughput compound screening in standard laboratory formats.

2RepliGut® Crypt
CategoryIn vitro human intestinal model platform
Description

An in vitro model derived from stem cells designed to replicate the complex cellular lifecycle of the intestinal crypt for drug discovery applications, capturing the crypt architecture of the human intestine for more physiologically relevant drug testing.

3RepliGut® Immune Co-Culture
CategoryIn vitro human intestinal model platform
Description

A human gut-immune co-culture model for evaluating inflammatory bowel disease anti-inflammatory therapies, enabling researchers to assess immune and epithelial interactions in a physiologically relevant format.

4RepliGut® Kits
CategoryBiological research kit product
Description

Ready-to-use kit products containing RepliGut® Planar models and media for compound screening, disease modeling, drug disposition analysis, and toxicity assessments in customer laboratories.

5Intestinal Mucus
CategoryBiological research product
Description

Human mucus harvested from the RepliGut® Planar platform for research related to gastrointestinal tract disorders, microbiome studies, and drug delivery investigations.

6InflammaScreen
CategoryContract research service
Description

Inflammation screening service using RepliGut® models to evaluate pro- and anti-inflammatory effects of new therapeutic modalities on human intestinal models.

7StemTox
CategoryContract research service
Description

Stem cell-based toxicity screening service for predicting gastrointestinal toxicity risk of therapeutic agents using RepliGut® models.

8In Vitro DMPK
CategoryContract research service
Description

Drug metabolism and pharmacokinetics service using human intestinal models to assess oral bioavailability, drug disposition, and ADME properties.

9Custom Services
CategoryContract research service
Description

Bespoke research collaborations tailored to specific client drug development needs, leveraging the RepliGut® Systems platform for custom preclinical studies.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1CN Bio Innovations
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Altis and CN Bio partnered to combine their RepliGut Planar-Jejunum and PhysioMimix Liver-on-a-Chip models, creating a primary human microphysiological system (MPS) that simulates oral drug administration. This Gut/Liver model enhances translation of in vitro studies to in vivo results and improves accuracy and predictability of data. It represents the next generation of CN Bio's oral bioavailability assay.

altisbiosystems.com
2Funakoshi, Ltd.
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Funakoshi, a Japanese leader in supplying research reagents and instruments for life science researchers, serves as an authorized distributor of all RepliGut Planar kits and RepliGut Media in Japan, enabling broader access to Altis products in the Japanese market.

altisbiosystems.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration in which RepliGut Planar Jejunum was evaluated for gene expression patterns in response to prototypical metabolic inducers (Rifampin, CITCO, 3-MC, and Calcitriol) at the 25th North American ISSX conference. Published scientific collaboration demonstrating platform utility.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct peer offering multi-organ MPS ("human-on-a-chip") for toxicology and ADME applications. Competes in the same multi-organ MPS category that Altis enters via its CN Bio partnership.

TypeDirect peer
Description

Direct peer providing the OrganoPlate platform for organ-on-chip and 3D tissue models used in preclinical drug discovery. Comparable customer base in pharma/biotech and similar NAMs positioning to Altis Biosystems.

3CN Bio Innovations
TypeDirect peer
Description

Direct peer and active partner, developing PhysioMimix single- and multi-organ MPS including Liver-on-a-Chip. Competitor in gut/liver ADME and oral bioavailability services, and co-developer with Altis on the Gut/Liver MPS.

TypeBroad incumbent
Description

Broad incumbent in 3D bioprinted tissue and disease modeling for preclinical research. Provides overlapping but more general 3D-tissue capabilities versus Altis's specialized intestinal organoid platform.

TypeBroad incumbent
Description

Broad incumbent life sciences instrument and cell-line screening vendor serving pharma/biotech R&D. Adjacent to Altis on the screening-tools and assay-readout side of NAMs workflows.

TypeDirect peer
Description

Direct peer in 3D microtissue and organotypic models for drug discovery and toxicology, including liver and pancreatic islet models. Overlaps with Altis on preclinical drug-discovery services and NAMs positioning.

TypeEmerging player
Description

Emerging player in vascularized organ-on-chip and 3D tissue models for drug discovery. Comparable NAMs positioning and overlapping pharma customer base to Altis Biosystems.

TypeEmerging player
Description

Emerging player in iPSC-derived human cell models (hepatocytes, intestinal, pancreatic) for drug discovery. Comparable technology base (iPSC-derived models) and customer base to Altis Biosystems.

TypeDirect peer
Description

Direct peer offering organ-on-chip platforms (Liver-Chip, Intestine-Chip, Lung-Chip) used for preclinical drug discovery. Comparable product category, customer base (large pharma), and NAMs regulatory positioning to Altis Biosystems.

TypeEmerging player
Description

Emerging player developing automated MPS platforms that leverage RepliGut cells. Direct technology integration partner and partial competitor in automated intestinal MPS offerings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Altis Biosystems

Preclinical Drug Discovery Toolsaltisbiosystems.com

Altis Biosystems is a Durham, NC-based biotechnology company developing RepliGut Systems, stem-cell-derived human intestinal epithelium models used by pharmaceutical and biotechnology companies for preclinical drug discovery, toxicology screening, and ADME/DMPK studies as alternatives to animal testing.

What Altis Biosystems does

Altis Biosystems is a privately held biotechnology company founded in 2015 and headquartered in Durham, North Carolina, that develops human intestinal epithelium models derived from adult donor stem cells for preclinical drug discovery and toxicology applications. Its core platform, RepliGut Systems, comprises RepliGut Planar (a reproducible, scalable human intestinal monolayer for drug disposition, pharmacology, ADME/DMPK, toxicity, and efficacy studies), RepliGut Crypt (capturing intestinal crypt architecture), and RepliGut Immune Co-Culture (a gut-immune model for inflammatory bowel disease research), complemented by catalog kit products and a human intestinal mucus offering.

The company monetizes through a hybrid B2B model: direct sales of ready-to-use kits and media products to pharma and biotech researchers, and fee-for-service contract research engagements including InflammaScreen (inflammation screening), StemTox (toxicity assessment), In Vitro DMPK, and custom research services. Pricing is not publicly disclosed; customers engage via website contact forms and direct sales outreach with multi-year contract terms typical of the life sciences tools segment. RepliGut products are positioned as New Approach Methodologies (NAMs) providing human-relevant, ethically sourced alternatives to animal testing for gastrointestinal toxicity prediction, drug absorption, metabolism, barrier function, and inflammatory response.

Altis serves pharmaceutical companies, biotechnology companies, and academic and contract research organizations, with named collaborations including Janssen R&D, Genentech, Fog Pharma, and CN Bio Innovations. The company maintains a scientific-publication-led go-to-market motion, leveraging peer-reviewed journals, conference presentations, and direct enterprise engagement, with Japan distribution handled via a partnership with Funakoshi, Ltd. As of April 2025, the company had raised approximately $6.6 million in disclosed equity funding across multiple rounds from investors including Hatteras Venture Partners, VentureSouth, and New Orleans BioFund, and operates with 11-50 employees organized around R&D, commercial strategy, operations, and quality assurance functions.

Altis Biosystems firmographics

Firmographics
Name
Altis Biosystems
Legal name
Altis Biosystems, Inc.
Website
https://altisbiosystems.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Altis Biosystems is a Durham, NC-based biotechnology company developing RepliGut Systems, stem-cell-derived human intestinal epithelium models used by pharmaceutical and biotechnology companies for preclinical drug discovery, toxicology screening, and ADME/DMPK studies as alternatives to animal testing.
Ownership category
akta.pro rank

Altis Biosystems industry classification

Industry
Product category
Preclinical Drug Discovery Tools
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Organ-on-chip models
  • Preclinical drug discovery
  • Human intestinal models
  • Stem cell assays
  • GI toxicity screening

Where Altis Biosystems is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Altis Biosystems business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. RepliGut Kit Sales: Sale of ready-to-use RepliGut Planar kits, RepliGut Crypt kits, and associated media products for compound screening, disease modeling, and microbiome research.
  2. Contract Research Services: Fee-for-service offerings including InflammaScreen (inflammation screening), StemTox (toxicity assessment), and In Vitro DMPK studies conducted on behalf of pharmaceutical and biotech clients.
  3. Custom Service Engagements: Bespoke research collaborations tailored to specific client drug development needs, leveraging the company's human intestinal model platform.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractContact-based pricing for all products and services

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Altis Biosystems product offering

Product offering

Core offering

Altis Biosystems develops and sells RepliGut Systems, a collection of in vitro human intestinal models derived from adult donor stem cells that replicate the structure of human small intestine and colonic epithelium. The portfolio includes RepliGut Planar, RepliGut Crypt, and RepliGut Immune Co-Culture platforms, complemented by ready-to-use RepliGut Kits, Intestinal Mucus products, and contract research services (InflammaScreen, StemTox, In Vitro DMPK, and Custom Services) for preclinical drug discovery, toxicology, ADME, and disease modeling applications.

Product overview

Altis Biosystems offers RepliGut® Systems, a collection of in vitro human intestinal models derived from stem cells, designed for pre-clinical drug discovery. The portfolio consists of three platform products (RepliGut® Planar, RepliGut® Crypt, and RepliGut® Immune Co-Culture) that replicate the complex structure of human small intestine and colonic epithelium. These are complemented by kit products (RepliGut® Kits and Intestinal Mucus) for laboratory use, and service offerings (InflammaScreen, StemTox, In Vitro DMPK, and Custom Services) that enable pharmaceutical companies to screen compounds for GI toxicity, evaluate inflammatory responses, and assess drug metabolism and bioavailability—all as alternatives to animal testing through New Approach Methodologies (NAMs).

Differentiator

Problem solved

Functional benefit

Products and services

  • RepliGut® Planar A reproducible and scalable human intestine platform derived from adult donor stem cells, suitable for studying drug disposition, pharmacology, toxicity, metabolism, drug absorption, and efficacy in preclinical drug discovery. Designed for high-throughput compound screening in standard laboratory formats.
  • RepliGut® Crypt An in vitro model derived from stem cells designed to replicate the complex cellular lifecycle of the intestinal crypt for drug discovery applications, capturing the crypt architecture of the human intestine for more physiologically relevant drug testing.
  • RepliGut® Immune Co-Culture A human gut-immune co-culture model for evaluating inflammatory bowel disease anti-inflammatory therapies, enabling researchers to assess immune and epithelial interactions in a physiologically relevant format.
  • RepliGut® Kits Ready-to-use kit products containing RepliGut® Planar models and media for compound screening, disease modeling, drug disposition analysis, and toxicity assessments in customer laboratories.
  • Intestinal Mucus Human mucus harvested from the RepliGut® Planar platform for research related to gastrointestinal tract disorders, microbiome studies, and drug delivery investigations.
  • InflammaScreen Inflammation screening service using RepliGut® models to evaluate pro- and anti-inflammatory effects of new therapeutic modalities on human intestinal models.
  • StemTox Stem cell-based toxicity screening service for predicting gastrointestinal toxicity risk of therapeutic agents using RepliGut® models.
  • In Vitro DMPK Drug metabolism and pharmacokinetics service using human intestinal models to assess oral bioavailability, drug disposition, and ADME properties.
  • Custom Services Bespoke research collaborations tailored to specific client drug development needs, leveraging the RepliGut® Systems platform for custom preclinical studies.

Quantifiable outcome

  • High-throughput assay for predicting diarrhea risk achieved 91% accuracy for proliferation, 90% for abundance, and 88% for barrier formation using RepliGut Planar model
  • +2 more outcomes

Companies that use Altis Biosystems

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Altis Biosystems technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

Altis Biosystems partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core, regional and minor.

  • CN Bio InnovationscoreStrategic or Co-development PartnerAltis and CN Bio partnered to combine their RepliGut Planar-Jejunum and PhysioMimix Liver-on-a-Chip models, creating a primary human microphysiological system (MPS) that simulates oral drug administration. This Gut/Liver model enhances translation of in vitro studies to in vivo results and improves accuracy and predictability of data. It represents the next generation of CN Bio's oral bioavailability assay.
  • Funakoshi, Ltd.regionalChannel Partner/ Reseller/ DistributorFunakoshi, a Japanese leader in supplying research reagents and instruments for life science researchers, serves as an authorized distributor of all RepliGut Planar kits and RepliGut Media in Japan, enabling broader access to Altis products in the Japanese market.
  • GenentechminorStrategic or Co-development PartnerResearch collaboration in which RepliGut Planar Jejunum was evaluated for gene expression patterns in response to prototypical metabolic inducers (Rifampin, CITCO, 3-MC, and Calcitriol) at the 25th North American ISSX conference. Published scientific collaboration demonstrating platform utility.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Altis Biosystems competitors and assessment

Company assessment

Direct peers

  • TissUse: Direct peer offering multi-organ MPS ("human-on-a-chip") for toxicology and ADME applications. Competes in the same multi-organ MPS category that Altis enters via its CN Bio partnership.
  • Mimetas: Direct peer providing the OrganoPlate platform for organ-on-chip and 3D tissue models used in preclinical drug discovery. Comparable customer base in pharma/biotech and similar NAMs positioning to Altis Biosystems.
  • CN Bio Innovations: Direct peer and active partner, developing PhysioMimix single- and multi-organ MPS including Liver-on-a-Chip. Competitor in gut/liver ADME and oral bioavailability services, and co-developer with Altis on the Gut/Liver MPS.
  • InSphero: Direct peer in 3D microtissue and organotypic models for drug discovery and toxicology, including liver and pancreatic islet models. Overlaps with Altis on preclinical drug-discovery services and NAMs positioning.
  • Emulate: Direct peer offering organ-on-chip platforms (Liver-Chip, Intestine-Chip, Lung-Chip) used for preclinical drug discovery. Comparable product category, customer base (large pharma), and NAMs regulatory positioning to Altis Biosystems.

Broad incumbents

  • Organovo: Broad incumbent in 3D bioprinted tissue and disease modeling for preclinical research. Provides overlapping but more general 3D-tissue capabilities versus Altis's specialized intestinal organoid platform.
  • Molecular Devices: Broad incumbent life sciences instrument and cell-line screening vendor serving pharma/biotech R&D. Adjacent to Altis on the screening-tools and assay-readout side of NAMs workflows.

Emerging players

  • Cypre Holdings (SynVivo/Cypher): Emerging player in vascularized organ-on-chip and 3D tissue models for drug discovery. Comparable NAMs positioning and overlapping pharma customer base to Altis Biosystems.
  • DefiniGEN: Emerging player in iPSC-derived human cell models (hepatocytes, intestinal, pancreatic) for drug discovery. Comparable technology base (iPSC-derived models) and customer base to Altis Biosystems.
  • Cellbox Labs: Emerging player developing automated MPS platforms that leverage RepliGut cells. Direct technology integration partner and partial competitor in automated intestinal MPS offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Altis Biosystems social profiles

Digital presence

Altis Biosystems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Altis Biosystems leadership team

Management profile

Number of profiles

Profiles11 records

Altis Biosystems funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Altis Biosystems M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Altis Biosystems

What does Altis Biosystems do?

Altis Biosystems develops and sells RepliGut Systems, a collection of in vitro human intestinal models derived from adult donor stem cells that replicate the structure of human small intestine and colonic epithelium. The portfolio includes RepliGut Planar, RepliGut Crypt, and RepliGut Immune Co-Culture platforms, complemented by ready-to-use RepliGut Kits, Intestinal Mucus products, and contract research services (InflammaScreen, StemTox, In Vitro DMPK, and Custom Services) for preclinical drug discovery, toxicology, ADME, and disease modeling applications.

Is Altis Biosystems a public or private company?

Altis Biosystems is a private company. It is classified as venture growth investor backed and is currently operating.

When was Altis Biosystems founded?

Altis Biosystems was founded in 2015. It employs 11 to 50 people.

Where is Altis Biosystems based?

Altis Biosystems is headquartered in Durham, United States, in the North America region.

How does Altis Biosystems make money?

Three revenue lines are on record. RepliGut Kit Sales are the primary driver. The others are contract Research Services and custom Service Engagements.

Who are Altis Biosystems's main competitors?

Direct peers on record are TissUse, Mimetas, CN Bio Innovations, InSphero and Emulate. Broad incumbents are Organovo and Molecular Devices. Emerging players are Cypre Holdings (SynVivo/Cypher), DefiniGEN and Cellbox Labs.

Does Altis Biosystems have an API?

No public API is recorded for Altis Biosystems.

What industry is Altis Biosystems in?

Altis Biosystems's product category is Preclinical Drug Discovery Tools. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAAGAD, Organoids & Organ-on-Chip (regenerative models). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SecSEC FORM DAltis Biosystems, Inc. filed a Form D notice with the Securities and Exchange Commission on April 7, 2025, notifying the agency of an exempt offering of equity securities under Rule 506(c). The company, incorporated in Delaware and based in Durham, North Carolina, is offering up to $2,250,000 in equity, with $2,126,307 already sold to 9 investors as of March 31, 2025. The filing indicates $123,693 remains to be sold under this offering.PharmafileCN Bio and Altis Biosystems partner for development of in vitro model for ADME studiesCN Bio and Altis Biosystems have partnered to develop an in vitro model for ADME studies. The article mainly reports on the collaboration between the two biotechnology companies.The ScientistTrust Your Gut: Screening Drugs Using Novel Intestinal ModelsResearchers face limitations with animal and in vitro models for drug ADME testing, as most GI adverse events are only found in clinical trials. Altis Biosystems' RepliGut systems use human intestinal stem cells to form monolayers, allowing access to both apical and basolateral surfaces for high-throughput screening.PR NewswireAltis Biosystems Launches RepliGut® Planar InflammaScreen Services to Accelerate Drug Discovery for Inflammatory Bowel DiseasesAltis Biosystems announced the launch of RepliGut® Planar InflammaScreen™ Services, a new package of standardized assays designed to screen potential therapeutics for inflammatory bowel diseases using human-derived in vitro models. The services provide researchers in early to mid-stage drug discovery with rapid, cost-effective testing capabilities, delivering results in as little as three weeks. This launch expands the company's portfolio of human cell-based model systems for pre-clinical drug development.NC State News2023 Plant and Microbial Biology Departmental Awards and RecognitionsNC State University's Department of Plant and Microbial Biology celebrated its spring 2023 graduates, awarding 21 Bachelor of Science, 13 Master of Microbial Biotechnology, and 5 graduate degrees. The department also recognized faculty promotions, student and faculty awards, and announced partnerships with Sensal Health, Altis Biosystems, and Cosmic Eats for practicum projects.American City Business JournalsPlakous Therapeutics receives research funding from Durham-based Altis Biosystems, will use Altis technology in new researchPlakous Therapeutics received a $10,000 research grant from Altis Biosystems to use the company's RepliGut technology in its research. The grant supports its lead drug, Protego-PD, for an upcoming investigational new drug filing. Plakous has raised about $4.5 million to date and plans to move the drug into toxicology studies in 2023.WRAL TechWireDurham startup Altis Biosystems offers grant for research incorporating its proprietaty techAltis Biosystems announced a second research grant program offering up to $10,000 for projects using its RepliGut planar model, with applications due Oct 3, 2022. The company previously awarded a grant to the Armed Forces Radiobiology Research Institute for studying radiation sickness. The program targets unmet need in early drug development risk assessment.DrugdiscoverynewsGut-On-A-Chip: Assessing Drug-induced Gut Toxicity In VitroAltis Biosystems will host a webinar on July 27, 2022, on using stem cell-based gut models to assess drug-induced GI toxicity. The session will cover challenges in GI risk assessment and an in vitro intestinal stem cell model, with a free pilot project available. Speakers include Bill Thelin and Bailey Zwarycz.HubsAltis Biosystems Offers Research Award for Use of Its RepliGut PlatformAltis Biosystems is offering a research award of up to $10,000 for scientists to use its RepliGut platform, which replicates the intestinal epithelium. Proposals are due by Nov. 15, with a project selected by Dec. 10 and work starting Jan. 15, 2022. The company aims to reduce drug development time and animal testing.UPSTATE BUSINESS JOURNALVentureSouth has invested more than $50 million in early-stage businessesVentureSouth, a Greenville investment company, has invested over $50 million in early-stage Southeast businesses, including North Carolina's Threatswitch and Altis Biosystems. The firm's portfolio spans software, healthcare, and industrial technologies, with companies raising over a billion dollars in follow-on capital and employing more than 2,000 people.